A comprehensive drug-drug interaction table and class review for rapid-acting insulin analogs (lispro, aspart, glulisine, faster aspart). Pharmacokinetics, DDI mechanisms, clinical management strategies, and dosing guidance for prescribers and pharmacists.
A clinician-level guide to managing adverse events from NAD precursors (NMN, NR, niacin), including dosing thresholds, monitoring parameters, drug interactions, and step-by-step mitigation protocols backed by primary-source evidence.
A clinician-level guide to NMN, NR, niacin, and nicotinamide, comparing pharmacokinetics, tissue delivery, clinical evidence, and practical prescribing decisions for NAD precursor therapy.
A board-reviewed clinical guide covering the PCSK9 inhibitor drug class, prescribing criteria, lipid and safety monitoring schedules, dose adjustments, and real-world outcomes data for evolocumab and alirocumab.
A clinician-level guide to selective estrogen receptor modulator (SERM) billing codes, prior-authorization strategies, step-therapy requirements, and appeal tactics for tamoxifen, raloxifene, clomiphene, toremifene, ospemifene, and enclomiphene.
A clinical-level review of selective estrogen receptor modulators (SERMs) in special populations including men, postmenopausal women, adolescents, and patients with renal or hepatic impairment. Covers enclomiphene, tamoxifen, raloxifene, ospemifene, and bazedoxifene with real doses, trials, and guidelines.
A prescriber-level guide to choosing among tamoxifen, raloxifene, clomiphene, enclomiphene, toremifene, and ospemifene based on tissue selectivity, clinical indication, and patient-specific risk factors.
A prescriber-level guide to recognizing, grading, and managing adverse events with siRNA lipid therapeutics, inclisiran, fitusiran, and related agents, covering injection-site reactions, liver effects, bleeding risk, and off-target monitoring.
A clinical reference for prescribers and pharmacists on managing statin adverse events: myopathy, hepatotoxicity, new-onset diabetes, and drug interactions, with specific monitoring thresholds and dose-adjustment protocols.
A prescriber-level monograph covering every FDA-approved testosterone formulation: pharmacokinetics, dosing, monitoring, adverse effects, and clinical decision frameworks for hypogonadism management.
A prescriber-level guide to levothyroxine dose titration, tapering, and monitoring. Covers starting doses, adjustment intervals, special populations, and evidence-based TSH targets from ATA and AACE guidelines.
A guide to the best supplements for brain fog, covering omega-3s, B vitamins, magnesium, lion's mane, citicoline, and when to consider prescription options instead.
Learn when and how to switch ADHD medications safely, including stimulant-to-stimulant, stimulant-to-non-stimulant, and modafinil transitions, with dose titration schedules and red-flag signs.
Repatha vs Leqvio: both cut LDL-C about 50% on statin therapy, but only Repatha has proven MACE data (FOURIER); Leqvio needs 2 office injections a year.
A clinical comparison of Wegovy (semaglutide 2.4 mg) and Ozempic (semaglutide 0.5 to 2.0 mg) covering FDA-approved indications, weight-loss efficacy, list prices, insurance coverage, and how to access each drug in 2025.
Wegovy (semaglutide 2.4 mg) and Ozempic (semaglutide 0.5 to 2.0 mg) share the same molecule but differ in dose, indication, and titration schedule. Learn when switching makes sense, how to do it safely, and what the clinical data actually say.
A head-to-head comparison of tirzepatide (Zepbound) and semaglutide (Ozempic), covering weight loss, glycemic control, side effects, and a step-by-step guide to switching between them safely.
A clinical comparison of sildenafil generic tablets versus alprostadil injection (Caverject) and suppository (MUSE) for erectile dysfunction, including when and how to switch between them.
Viagra and generic sildenafil contain the same active molecule at the same doses. This guide explains bioequivalence, how to switch safely, dosing differences, cost comparisons, and what clinical evidence actually says.
A clinical comparison of enclomiphene citrate and Jatenzo (oral testosterone undecanoate) for male hypogonadism, including how and when to switch between them, with primary-source citations throughout.
A detailed clinical comparison of testosterone enanthate injections versus AndroGel (testosterone gel 1.62%) side-effect profiles, dosing, transfer risk, and which format suits different patients.
A direct clinical comparison of tesamorelin (Egrifta) and ibutamoren (MK-677) covering mechanism, evidence quality, cost, legal status, and who should use each compound.
Compare the research identities, evidence gaps, and advertised pricing assumptions behind BPC-157 and TB-500 without treating them as established therapies.
A clinical comparison of PT-141 (bremelanotide) and MOTS-c, covering mechanisms, trial data, dosing, and how to approach switching between these two specialty peptides.
A clinical comparison of thymosin alpha-1 (thymalfasin) and MOTS-c mitochondrial peptide side-effect profiles, mechanisms, dosing, and ideal patient selection, prepared by the HealthRX.com Editorial Team.
A comparison of zolpidem (Ambien) and lemborexant (Dayvigo) covering mechanism, efficacy, safety, and how to safely switch between them.
A timeline of male hypogonadism treatment from 19th-century organotherapy through modern testosterone formulations, GnRH-based therapies, and emerging peptide research, with an evidence-boundary review of which historical claims are well established and which are not settled.
Male hypogonadism is frequently overlooked or mistaken for depression, aging, or thyroid disease. Learn which conditions mask low testosterone, how to confirm the diagnosis, and how to manage it correctly.
A guide for partners and families of men with hypogonadism covering diagnosis criteria, treatment options, communication strategies, and how to support TRT or other therapy from day one.
Learn which menopause-related symptoms are true medical emergencies requiring 911, how to distinguish them from typical hot flashes and palpitations, and what treatments reduce long-term cardiovascular and bone risk.
A guide to stopping HRT and menopausal hormone therapy safely, including tapering schedules, symptom management, bone protection strategies, and major society guidelines.
A clinical timeline of menopause treatment from the 1940s to today, covering estrogen therapy, the WHI trial, and current hormone and non-hormone options with guideline-based guidance.
An evidence-based overview of how common menopause-related weight gain is worldwide, which populations are most affected, and what the data say about body composition shifts during the menopausal transition.
NIH first-line obesity treatment: a 500-750 kcal/day deficit plus 150-300 min/week exercise, yielding 5-10% weight loss in 6 months to cut cardiometabolic risk.
How OSA diagnosis and first-line treatment differ across pregnant women, children, older adults, people with obesity, and people with cardiovascular disease or diabetes, including where tirzepatide and CPAP fit and where the evidence is still incomplete.
The 2023 International PCOS Guideline recommends 150 minutes of moderate aerobic exercise weekly plus 2 resistance sessions, improving insulin sensitivity.
Learn how to stop perimenopause treatments safely, including HRT, low-dose oral contraceptives, and non-hormonal therapies. Evidence-based tapering protocols, withdrawal timelines, and society guideline recommendations.
Perimenopause is misdiagnosed as depression, thyroid disease, anxiety, ADHD, and more. Learn which conditions get confused, why labs mislead, and how to get the right diagnosis.
Does tendinopathy run in families? Explore the genetic variants, heritability data, and clinical implications that shape diagnosis and treatment of chronic tendon disease.
A direct comparison of major society guidelines on tendinopathy diagnosis and treatment, including load management, eccentric exercise, PRP, BPC-157, and emerging peptide therapies. prepared by the HealthRX.com Editorial Team.
A guide to exercise protocols for type 2 diabetes, covering aerobic, resistance, and combined training, ADA and AACE dose recommendations, glycemic outcomes, and how to structure a safe, effective weekly plan.
A guide to stopping PCOS treatments safely, including metformin, GLP-1 receptor agonists, oral contraceptives, and spironolactone. Covers withdrawal effects, rebound risks, and how to taper each medication class.
A decision framework for first-line PCOS management covering lifestyle, metformin, hormonal contraception, and GLP-1 receptor agonists, with citations from Endocrine Society, ADA, and primary trial data.
PCOS affects 6 to 12% of reproductive-age women yet takes an average of 2 years and 3 clinicians to diagnose correctly. Learn which conditions mimic PCOS, which PCOS-related conditions get missed, and how the 2023 international guidelines changed the diagnostic framework.
A deep dive into the most contested clinical questions in established cardiovascular disease, from optimal LDL targets to the role of GLP-1 agonists, polypharmacy debates, and residual inflammatory risk.
A overview of established cardiovascular disease worldwide, covering prevalence data, regional burden, mortality trends, and guideline-based risk context for patients and providers.
Cardiovascular treatment gaps by race and ethnicity: primary studies, stroke data, secondary prevention and practical ways to improve access and follow-up.
A guide to rare and atypical presentations of established cardiovascular disease, including silent MI, vasospastic angina, Kounis syndrome, cardiac syndrome X, MINOCA, and Takotsubo cardiomyopathy, with an evidence-boundary map and a bedside screening framework.
A look at how many people experience menopause worldwide, regional age-at-menopause differences, rising life-expectancy implications, and what epidemiological trends mean for treatment planning.
A deep dive into the emerging mechanisms driving metabolic syndrome, covering gut microbiome dysbiosis, inflammasome activation, mitochondrial dysfunction, epigenetic reprogramming, and adipokine signaling, with primary-source citations throughout.
A guide to racial and ethnic disparities in metabolic syndrome prevalence, diagnosis, and treatment, with primary-source citations and practical clinical guidance.
A clinical deep-dive into the rare and atypical presentations of metabolic syndrome, including lean MetS, pediatric cases, PCOS overlap, lipodystrophy, and normal-weight obesity. Includes guidelines, trial data, and a decision framework.
A detailed breakdown of the socioeconomic burden of NAFLD/MASLD: healthcare costs, lost productivity, disability, health disparities, and what updated MASLD criteria mean for population-level projections.
An evidence-based overview of obstructive sleep apnea global prevalence, regional trends, risk factors, and clinical burden, prepared by the HealthRX.com Editorial Team.
Beyond the classic triad of irregular periods, hyperandrogenism, and polycystic ovaries, PCOS can appear in ways that delay diagnosis for years. Learn the uncommon phenotypes, diagnostic pitfalls, and evidence-based workup strategies.
A clinical history of how tendinopathy treatment has evolved from rest and corticosteroids to eccentric loading, biologics, and emerging peptide therapies. prepared by the HealthRX.com Editorial Team.
A look at how race and ethnicity shape tendinopathy risk, diagnosis rates, treatment access, and outcomes, with primary-source citations throughout.
An evidence-based guide to rare and atypical tendinopathy presentations, including fluoroquinolone-induced tendinopathy, calcific variants, systemic disease associations, and bilateral spontaneous ruptures. prepared by the HealthRX.com Editorial Team.
A clinical deep-dive into the rare and atypical presentations of type 2 diabetes, including euglycemic DKA, latent autoimmune diabetes in adults, ketosis-prone T2D, and more. Includes statistics, guideline quotes, and original frameworks.
Stopping Farxiga (dapagliflozin) can trigger fluid retention, blood sugar rebound, and worsening heart failure within days. This evidence-based guide covers the mechanism, timelines, clinical trial data, and how to stop safely.